|
WO2007136626A1
|
|
Solid dosage formulations of hydralazine compounds
|
|
EP2010169A2
|
|
Assessment of heart failure risk using genetic assessment of g-protein beta-3 subunit polymorphism
|
|
WO2007123818A2
|
|
Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use
|
|
WO2007126609A1
|
|
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
|
US2008293724A1
|
|
Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
|
|
US2009053328A1
|
|
Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use
|
|
US2008293702A1
|
|
Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use
|
|
EP1954685A2
|
|
Furoxan compounds, compositions and methods of use
|
|
US2009253662A1
|
|
Genetic risk assessment in heart failure: impact of genetic variation of aldosterone synthase promoter polymorphism
|
|
AU2006299383A1
|
|
Methods for treating respiratory disorders
|
|
EP1945030A2
|
|
The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
|
|
EP1922069A2
|
|
Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use
|
|
WO2007016677A2
|
|
Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
|
|
WO2007016136A2
|
|
Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
|
|
WO2007016095A2
|
|
Cyclooxygenase-2 selective inhibitor compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
|
WO2006127591A2
|
|
Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
|
|
EP1865770A2
|
|
The genetic risk assessment in heart failure: impact of the genetic variation of nos3
|
|
WO2006099416A1
|
|
2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
|
EP1861093A2
|
|
Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
|
|
EP1858863A1
|
|
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
